ARCA biopharma Provides Update on ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19
ARCA biopharma, Inc. (ABIO)
US:NASDAQ Investor Relations:
arcabio.com/investors
Company Research
Source: GlobeNewswire
rNAPc2 development focused on unmet need for treatments in hospitalized COVID-19 patientsTrial expanded to South America, with regulatory approvals for Argentina and BrazilTarget trial enrollment increased to 160 patientsTopline trial data anticipated in the fourth quarter of 2021 WESTMINSTER, Colo., July 13, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today provided an update on ASPEN-COVID-19, the Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for patients hospitalized with COVID-19. ARCA has received approval from regulatory authorities in Argentina and Brazil to enroll patients in ASPEN-COVID-19. The trial is currently enrolling patients at seven investigative sites in the United States. The Company anticipates enrolling the first South American patients in July 2021. Trial target enrollment is bei
Show less
Read more
Impact Snapshot
Event Time:
ABIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABIO alerts
High impacting ARCA biopharma, Inc. news events
Weekly update
A roundup of the hottest topics
ABIO
News
- ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswire
- ARCA biopharma, Inc. (NASDAQ: ABIO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- ARCA biopharma, Inc. (NASDAQ: ABIO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ANSS, HRT, CHX, ABIOPR Newswire
ABIO
Sec Filings
- 4/25/24 - Form 425
- 4/25/24 - Form 8-K
- 4/25/24 - Form 10-Q
- ABIO's page on the SEC website